Clinical trials
Observational Ataxia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 8 |
| Completed | 6 |
| Unknown status | 5 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boston Children's Hospital | 2 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 2 |
| The Methodist Hospital Research Institute | 2 |
| Brigham and Women's Hospital | 1 |
| Children's Hospital of Philadelphia | 1 |
| Friedreich's Ataxia Research Alliance | 1 |
| Global Healthy Living Foundation | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| National Pediatric Neuroinflammation Organization, Inc. | 1 |
| Oregon Health and Science University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ataxia | 20 |
| Friedreich Ataxia | 6 |
| Epilepsy | 5 |
| Chorea | 3 |
| Movement Disorders | 3 |
| Myoclonus | 3 |
| Deafness | 2 |
| Diabetes Mellitus | 2 |
| Dyskinesias | 2 |
| Dystonic Disorders | 2 |
Trials
Showing 1 to 20 of 20. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.